Anneke Blackburn

Anneke Blackburn

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2009 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
RSramon sun
ramon sun
MFMitali Fadia
Mitali Fadia
JDJane Dahlstrom
Jane Dahlstrom
CPChristopher Parish
Christopher Parish
PBPhilip G. Board
Philip G. Board
ABAnneke Blackburn
Anneke Blackburn

13 January 2001 in Biochemistry
Verified
Journal Article
Closed access
GPGalina Polekhina
Galina Polekhina
PBPhilip G. Board
Philip G. Board
ABAnneke Blackburn
Anneke Blackburn
MPMichael Parker
Michael Parker

18 November 2011 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
RSramon sun
ramon sun
PBPhilip G. Board
Philip G. Board
ABAnneke Blackburn
Anneke Blackburn
Background: Cancer cells have a different metabolic profile compared to normal cells. The Warburg effect (increased aerobic glycolysis) and glutaminolysis (increased mitochondrial activity from glutamine catabolism) are well known hallmarks of cancer and are accompanied by increased lactate production, hyperpolarized mitochondrial membrane and increased production of reactive oxygen species. Methods: In this study we target the Warburg effect with dichloroacetate (DCA) and the increased mitochondrial activity of glutaminolysis with arsenic trioxide (ATO) in breast cancer cells, measuring cell proliferation, cell death and mitochondrial characteristics. Results: The combination of DCA and ATO was more effective at inhibiting cell proliferation and inducing cell death than either drug alone. We examined the effect of these treatments on mitochondrial membrane potential, reactive oxygen species production and ATP levels and have identified new molecular mechanisms within the mitochondria for both ATO and DCA: ATO reduces mitochondrial function through the inhibition of cytochrome C oxidase (complex IV of the electron transport chain) while DCA up-regulates ATP synthase β subunit expression. The potentiation of ATO cytotoxicity by DCA is correlated with strong suppression of the expression of c-Myc and HIF-1α, and decreased expression of the survival protein Bcl-2. Conclusion: This study is the first to demonstrate that targeting two key metabolic hallmarks of cancer is an effective anti-cancer strategy with therapeutic potential.

3 March 2000 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
HTHuey-Fen Tzeng
Huey-Fen Tzeng
ABAnneke Blackburn
Anneke Blackburn
PBPhilip G. Board
Philip G. Board
MAM. W. Anders
M. W. Anders

1 February 2000 in Pharmacogenetics
Verified
Journal Article
Closed access
ABAnneke Blackburn
Anneke Blackburn
HTHuey-Fen Tzeng
Huey-Fen Tzeng
MAM. W. Anders
M. W. Anders
PBPhilip G. Board
Philip G. Board
Analysis of the expressed sequence tag (EST) database by sequence alignment allows a rapid screen for polymorphisms in proteins of physiological interest. The human zeta class glutathione transferase GSTZ1 has recently been characterized and analysis of expressed sequence tag clones suggested that this gene may be polymorphic. This report identifies three GSTZ1 alleles resulting from A to G transitions at nucleotides 94 and 124 of the coding region, GSTZ1*A – A94A124;GSTZ1*B – A94G124;GSTZ1*C – G94G124. Polymerase chain reaction/restriction fragment length polymorphism analysis of a control Caucasian population (n = 141) showed that all three alleles were present, with frequencies of 0.09, 0.28 and 0.63 for Z1*A, Z1*B and Z1*C, respectively. These nucleotide substitutions are non-synonymous, with A to G at positions 94 and 124 encoding Lys32 to Glu and Arg42 to Gly substitutions, respectively. The variant proteins were expressed in Escherichia coli as 6X His-tagged proteins and purified by Ni-agarose column chromatography. Examination of the activities of recombinant proteins revealed that GSTZ1a–1a displayed differences in activity towards several substrates compared with GSTZ1b–1b and GSTZ1c–1c, including 3.6-fold higher activity towards dichloroacetate. This report demonstrates the discovery of a functional polymorphism by analysis of the EST database.

1 February 2006 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
ABAnneke Blackburn
Anneke Blackburn
KMKlaus I. Matthaei
Klaus I. Matthaei
CLCindy Lim
Cindy Lim
MTMatthew Taylor
Matthew Taylor
JCJean Y. Cappello
Jean Y. Cappello
PBPhilip G. Board
Philip G. Board
Glutathione S-transferase (GST) zeta (GSTZ1-1) plays a significant role in the catabolism of phenylalanine and tyrosine, and a deficiency of GSTZ1-1 results in the accumulation of maleylacetoacetate and its derivatives maleylacetone (MA) and succinylacetone. Induction of GST subunits was detected in the liver of Gstz1–/– mice by Western blotting with specific antisera and high-performance liquid chromatography analysis of glutathione affinity column-purified proteins. The greatest induction was observed in members of the mu class. Induction of NAD(P)H:quinone oxidoreductase 1 and the catalytic and modifier subunits of glutamate-cysteine ligase was also observed. Many of the enzymes that are induced in Gstz1–/– mice are regulated by antioxidant response elements that respond to oxidative stress via the Keap1/Nrf2 pathway. It is significant that diminished glutathione concentrations were also observed in the liver of Gstz1–/– mice, which supports the conclusion that under normal dietary conditions, the accumulation of electrophilic intermediates such as maleylacetoacetate and MA results in a high level of oxidative stress. Elevated GST activities in the livers of Gstz1–/– mice suggest that GSTZ1-1 deficiency may alter the metabolism of some drugs and xenobiotics. Gstz1–/– mice given acetaminophen demonstrated increased hepatotoxicity compared with wild-type mice. This toxicity may be attributed to the increased GST activity or the decreased hepatic concentrations of glutathione, or both. Patients with acquired deficiency of GSTZ1-1 caused by therapeutic exposure to dichloroacetic acid for the clinical treatment of lactic acidosis may be at increased risk of drug- and chemical-induced toxicity.